Lexston Life Sciences Corp. (TSE:LEXT)
:LEXT
Want to see TSE:LEXT full AI Analyst Report?
LEXT Stock Chart & Stats
C$0.10
<C$0.01(11.11%)
At close: 4:00 PM EST
C$0.10
<C$0.01(11.11%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.34
Previous CloseN/A
Volume1.00M
Average Volume (3M)40.70K
Market Cap
C$1.25M
Enterprise ValueC$89.61K
Total Cash (Recent Filing)C$278.52K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta-0.32
Next Earnings
Sep 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding25,093,304
10 Day Avg. Volume77,591
30 Day Avg. Volume40,703
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)13.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtZero reported debt materially reduces leverage risk and preserves financial flexibility, lowering near-term default and interest burden. Over 2–6 months this supports the company’s ability to fund operations via equity or limited external financing and protects downside in stressed metal cycles.
Prior Revenue And Gross Profit HistoryPast periods of revenue and positive gross profit indicate the business has operational capability and potential product/asset monetization pathways. This historical track record suggests management can redeploy or restart revenue-generating activities rather than being a pure perpetual development-stage issuer.
Improving Free Cash Flow TrendAn improving TTM free cash flow trend signals progress toward reducing cash burn and moving closer to self-funding operations. If sustained, this trajectory raises the chance of extended runway, fewer financing rounds, and stronger resilience through cyclical downturns in the gold sector.
Bears Say
No Recent Revenue And Persistent LossesAbsence of recurring revenue and sustained net losses indicate the company lacks a durable earnings engine. Over a multi-month horizon this undermines operating viability, forces reliance on external funding, and reduces the probability of achieving self-sustaining margins without strategic change or asset monetization.
Negative Operating Cash FlowConsistent negative operating cash flow shows the business consumes cash in normal operations, increasing financing and runway risk. Over 2–6 months this elevates the chance of dilutive capital raises or constrained capital allocation, limiting investments needed to restart sustainable growth or operations.
Negative Returns On Equity; Volatile Equity BasePersistent negative ROE and volatile equity signal an inability to compound shareholder capital and sustained value destruction. Structurally, this hampers investor confidence and lengthens the timeline for recovery, making it harder to attract long-term capital or strategic partners without clear operational turnaround.
Lexston Life Sciences Corp. News
LEXT FAQ
What was Lexston Life Sciences Corp.’s price range in the past 12 months?
Lexston Life Sciences Corp. lowest stock price was C$0.05 and its highest was C$0.34 in the past 12 months.
What is Lexston Life Sciences Corp.’s market cap?
Lexston Life Sciences Corp.’s market cap is C$1.25M.
When is Lexston Life Sciences Corp.’s upcoming earnings report date?
Lexston Life Sciences Corp.’s upcoming earnings report date is Sep 21, 2026 which is in 119 days.
How were Lexston Life Sciences Corp.’s earnings last quarter?
Lexston Life Sciences Corp. released its earnings results on Apr 03, 2026. The company reported -C$0.016 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.016.
Is Lexston Life Sciences Corp. overvalued?
According to Wall Street analysts Lexston Life Sciences Corp.’s price is currently Overvalued.
Does Lexston Life Sciences Corp. pay dividends?
Lexston Life Sciences Corp. does not currently pay dividends.
What is Lexston Life Sciences Corp.’s EPS estimate?
Lexston Life Sciences Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lexston Life Sciences Corp. have?
Lexston Life Sciences Corp. has 25,093,304 shares outstanding.
What happened to Lexston Life Sciences Corp.’s price movement after its last earnings report?
Lexston Life Sciences Corp. reported an EPS of -C$0.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lexston Life Sciences Corp.?
Currently, no hedge funds are holding shares in TSE:LEXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lexston Life Sciences Corp.
Lexston Life Sciences Corp. operates as a biotechnology company that provides cannabis testing and research services in Canada. The company also offers analytical testing for cannabis, pathogens, and toxins. In addition, it focuses on developing and validating methods for standardized manufacturing of plant derived psychedelics in the field of mental health and wellness. The company is based in Vancouver, Canada.
Technical Analysis
Options Prices
Currently, No data available
---